Stryker Co. (NYSE:SYK) is LaFleur & Godfrey LLC’s 5th Largest Position

LaFleur & Godfrey LLC lessened its holdings in Stryker Co. (NYSE:SYK) by 2.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 76,029 shares of the medical technology company’s stock after selling 2,230 shares during the quarter. Stryker accounts for about 3.8% of LaFleur & Godfrey LLC’s holdings, making the stock its 5th biggest position. LaFleur & Godfrey LLC’s holdings in Stryker were worth $27,374,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Parnassus Investments LLC purchased a new position in shares of Stryker in the 3rd quarter valued at about $762,798,000. International Assets Investment Management LLC grew its position in Stryker by 66,967.5% during the third quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock worth $308,433,000 after buying an additional 852,496 shares during the period. RTW Investments LP purchased a new position in Stryker in the third quarter valued at about $143,392,000. State Street Corp lifted its position in shares of Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock valued at $5,279,788,000 after acquiring an additional 316,404 shares during the period. Finally, FMR LLC boosted its stake in shares of Stryker by 3.0% during the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after acquiring an additional 215,782 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. BTIG Research lifted their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price target on Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Evercore ISI lifted their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is owned by corporate insiders.

Stryker Price Performance

Stryker stock opened at $383.91 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company has a market cap of $146.35 billion, a price-to-earnings ratio of 41.15, a PEG ratio of 2.51 and a beta of 0.95. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20. The firm has a 50 day moving average price of $375.51 and a 200 day moving average price of $358.98.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the company posted $2.46 EPS. Sell-side analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker’s payout ratio is presently 36.01%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.